Basic Information
AMINOVEN SOLUTION FOR INFUSION 15%
INFUSION, SOLUTION
Regulatory Information
SIN16337P
September 30, 2021
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XB05BA01
Company Information
FRESENIUS KABI (SINGAPORE) PTE LTD
FRESENIUS KABI (SINGAPORE) PTE LTD
Active Ingredients
Strength: 5.5g/L
Strength: 9.6g/L
Strength: 1.6g/L
Strength: 18.5g/L
Strength: 11.1g/L
Strength: 2g/L
Strength: 5.5g/L
Strength: 3.8g/L
Strength: 0.4g/L
Strength: 5.2g/L
Strength: 8.6g/L
Strength: 7.3g/L
Strength: 25g/L
Strength: 8.9g/L
Strength: 20g/L
Strength: 17g/L
Detailed Information
Contraindications
**Contraindications** As for all amino acid solutions, the administration of **Aminoven 15%** is contraindicated in the following conditions: Disturbances of amino acid metabolism, metabolic acidosis, renal insufficiency without haemodialysis or haemofiltration treatment, advanced liver insufficiency, fluid overload, shock, hypoxia, decompensated heart failure. The administration of **Aminoven 15%** is contraindicated in children. For parenteral nutrition of infants and children paediatric amino acid preparations should be used, which are formulated to meet the different metabolic needs of children. No clinical studies have been conducted with **Aminoven 15%** solution in newborns, infants or children.
Indication Information
**Therapeutic indications** For supply of amino acids, as part of a parenteral nutrition regimen. **Aminoven 15%** is mainly indicated if during parenteral nutrition therapy the fluid volume has to be restricted. Amino acid solutions should be administered generally in combination with adequate amount of energy supplements.